Peptides Mimicking the SHBG Function

Innovation to reduce Ectopic Fat Accumulation

Endolipid is developing application in Cellulite and NASH

Vall d'Hebron Recerca

The Team

David M Selva, PhD CSO

David M. Selva, PhD

Board Member and Scientific Leader / Worldwide expert and KOL on SHBG / Extensive experience on molecular mechanisms regulating SHBG and its role in human disease development / More than 30 papers published in top international journals.

Albert Palomer, PhD CEO

Albert Palomer, PhD

Senior Executive and Development Consultant / Former CEO ABAC Therapeutics and Head of Med Chemistry at Ferrer and Menarini / Boards member and advisor to start-ups in Spain, Belgium, Germany and S Africa / Co-developer of the NSAID analgesic Enantyum® and the quinolone antibiotic Ozanex® / Delivered pre-candidates for pain, inflammation, CNS, malaria and antibacterial therapies.

Rafael Simó, MD, Prof CMO

Rafael Simó, MD, Prof

Head of Endocrinology and Nutrition Department / Deputy Director of Clinical Research at Campus Vall d’Hebron / Professor of Medicine & Endocrinology. Universitat Autònoma de Barcelona / President of the European Association for the Study of Diabetes- Eye Complications.

Martí Archs
Project Manager

Laura Brianso
PhD Student

Pablo Gabriel
PhD Student

Lorena Ramos
Lab Technician

Endolipid Therapeutics

Who are we?

Science meets Business

Team combining basic and clinical research with management in biotech/pharma

Vall d'Hebron Recerca

After basic research at VHIR, the spin-off was created in April 2021

Genesis Ventures

Supported by Genesis


Peptide nanoformulation for long-lasting and targeted drug delivery

What we do?

How we do?

Reduce ectopic fat

Mimicking SHBG: A new mechanism of action to reduce ectopic fat, with strong science fundament and interesting applications

Cellulite and NASH

Peptides EDL3D and EDL6D for celluite and NASH applications

How we do?

2-Speed business model

Business model with short- and long-term assets that allow an early return in 2023

Bridge investment

Bridge investment of 500.000€ through Cap Cell

Pathologies Derived from Fat Accumulation

Increased ectopic fat accumulation:

Fatty liver and NASH

  • Liver fat accumulation, fibrosis and inflammation leading to cirrhosis.
  • Silent disease, low awareness and poor diagnosis.
  • Co-morbidities obesity, diabetes, hyperlipidemia and hypertension.
Cellulite - Subcutaneous fat


  • Undesirable fat deposits in subcutaneous adipocyte.
  • Socially subterfuge disease affecting +80% pot-puberal females.
  • Scarce science-based innovation in the last decade.
Arrow down

Endolipid proposed strategy:

Sex Hormone Binding Globulin (SHBG)

Mimicking SHBG, an innovative new strategy to reduce ectopic fat accumulation.


Sex Hormone-Binding Globulin

  • Plasma glycoprotein
  • Produced by the liver and secreted Into the blood.
  • Binds sex steroids.
  • Low plasma SHBG levels related to subjects with obesity, fatty liver, type 2 diabetes and PCOS.
SHBG alternative functions
SHBG alternative functions

Lipolysis (1)
Lipogenesis (2,3)
Fibrosis (4)
Inflammation (3,5)
Dr. David M Selva from the VHIR research group is world leader in SHBG biology.

(1) Lipolysis: Sáez-López et al 2020 J Nutr Biochem.
(2) Lipogenesis: Sáez-López et al 2015 and 2017 Endocrinology.
(3) Lipogenesis, Inflammation: Sáez-López et al 2019 JCEM),
(4) Fibrosis: Selva DM et al unpublished.
(5) Inflammation: Yamazaki H et al 2018 Mediators Inflamm.

The ENDOLIPID Technology.
SHBG-mimic Peptides

Peptides mimicking SHBG are useful to treat fatty liver diseases and reduce cellulite.
Therapeutic and dermocosmetic applications.

SHBG reduces liver fat accumulation
SHBG reduces liver fat accumulation
SHBG-mimic: EDL Technology®
EDL3D peptide: Innovation in dermocosmetics.
EDL6D peptide: Innovation in NASH therapeutics
EDL3D - Cellulite: Reduce subcutaneos fat
EDL6D - Fatty liver and Nash: Prevent and treat visceral adiposity

Endolipid (EDL) Peptide Products

Mimicking SHBG, an innovative approach to NASH and cellulite thin pipelines.

Two peptides, EDL3D (Cellulite) is ready for co-development and EDL6D (NASH) is in PoC.

EDL3D Cellulite

EDL3D – Cellulite.

  • New MoA with strong science fundaments
  • Strong lipolytic effect
  • Favourable safety profile
  • Peptide ready for co-development and license-out
ADL6D Nash


  • New MoA with strong science fundaments
  • Outstanding efficacy hitting the 4 causes of the disease
  • Favourable safety profile
  • Peptide in in vivo validation in mice (PoC)

Supported by:


EndoLipiD Therapeutics

Vall d’Hebrón Institut de Recerca (VHIR)
Laboratori 114 – Edifici Mediterrànea

Passeig de la Vall d’Hebrón 119-129
08035 Barcelona, Spain